Patent · US Active

Inhibiting the transient receptor potential A1 ion channel

US10428072B2 · kind B2 · utility

1Cited by

0References

58Claims

0Family size

Assignee

ELI LILLY AND COMPANY · US

Inventors

Blaise S. Lippa · Newton, US
Xinyuan Wu · Newton, US
Qingyi Li · Somerville, US
Iwona Wrona · Sharon, US
Andrew J. Jackson · Waltham, US
Bertrand L. Chenard · Waterford, US
Christopher Matthew Liu · Cambridge, US
Guohua Liang · Acton, US
Matthew Baevsky · Brookline, US
Richard A. Earl · Wilmington, US
Lisa Mcqueen · Phoenixville, US
Jared P. Smit · Lafayette, US
Brett A. Cowans · Lafayette, US

Key dates

Filing date	Mar 29, 2018
Grant date	Oct 1, 2019
Priority date	—
Expiry date	Mar 29, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.